BHS

Belgian Hematology Society

38th General Annual Meeting of the Belgian Hematology Society

February 3-4, 2023

Face to face Meeting

www.bhs.be

BHS transplantation committee

Tessa Kerre, Ghent University Hospital
Carlos Graux, UCL

BHS
Belgian Hematology Society

38th General Annual Meeting of
the Belgian Hematology Society

February 3-4, 2023
Face to face Meeting

Members

Chair: Tessa Kerre, UZ Gent

Co-chair: Carlos Graux, UCL

Members: representatives from all Belgian transplant centers

CRA:

Josephine Muller (CRA Ulg)

Email address: clinicaltrials@bhs.be

Members

AZ Delta Roeselare: Dries Deeren (Dries.Deeren@azdelta.be)

AZ Sint-Jan Brugge: Dominik Selleslag (dominik.selleslag@azsintjan.be), Tom Lodewyck (Tom.Lodewyck@azsintjan.be), Alexander Schauwlieghe (alexander.schauwvlieghe@azsintjan.be)

Institut Bordet: Philippe Lewalle (philippe.lewalle@bordet.be), Sebastian Wittnebel (Sebastian.wittnebel@bordet.be)

Jessa Ziekenhuis Hasselt: Koen Theunissen (koen.theunissen@jessazh.be)

UCL: Carlos Graux (carlos.graux@uclouvain.be), Xavier Poiré (xavier.poire@uclouvain.be), Florence Van Obbergh (vanobbergh.florence@uclouvain.be)

Ulg: Yves Beguin (yves.beguin@chu.ulg.ac.be), Frédéric Baron (F.Baron@ulg.ac.be), Evelyne Willems (E.Willems@chu.ulg.ac.be), Sophie Servais (s.servais@chu.ulg.ac.be)

UZ Antwerpen: Anke Verlinden (Anke.Verlinden@uza.be)

UZ Brussel: Ann De Becker (Ann.DeBecker@uzbrussel.be), Rik Schots (rik.schots@az.vub.ac.be), Dorien Deneve Dorien (dorien.deneve@uzbrussel.be)

UZ Gent: Anke Delie (Anke.Delie@uzgent.be), Tessa Kerre (tessa.kerre@ugent.be)

UZ Leuven: Johan Maertens (Johan.Maertens@uz.kuleuven.ac.be), Hélène Schoemans (helene.schoemans@uz.kuleuven.ac.be), marielle.beckers@uzleuven.be" (marielle.beckers@uzleuven.be)

ZNA: Dimitri Breems (dimitri.breems@zna.be), Karolien Beel (karolien.beel@zna.be)

Overview past and current trials

End of Study:

- TJB0603 (EBMT)
- TJB0702 (Flu-TBI vs TLI-ATG)
- TJB0905 (MSC CB)
- TJB0909 (MSC mismatched)
- TJB1010 (HOVON96)
- TJB1016 (Rapa vs MMF)
- TJB1122 (Busulfan)
- TJB1302 (DLI Vidaza)
- TJT1401 (CMV)

Recruiting Studies:

- TJB0703 (MSC poor chimerism)
- TJT1203 (WIDEA) → AML committee
- TJB1305 (Photopheresis)
- TJB1703 (FM-PTCy vs FM-ATG)
- TRACE

Current trials



Refractory EBV/CMV/ADV infections post allo-SCT with seropositive donor

TRACE (Horizon 2020)
CMV/EBV/Adv specific T cells after SCT
2021-2024
(T Kerre, UZG)

UZG
UZB
UZL
Ulg
AZ St-Jan Brugge?

What did we do in 2022?

Publications on clinical trials

Accepted

Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian Hematology Society (BHS).

Poiré X, Graux C, Ory A, Herman J, Baron F, Schoemans H, Lewalle P, De Becker A, Deeren D, Berneman Z, Kerre T, Zachée P, Selleslag D, Beguin Y.Bone Marrow Transplant. 2022 Jan;57(1):116-118. doi: 10.1038/s41409-021-01464-x. Epub 2021 Oct 5.

What did we do in 2022?

Publications on clinical trials

Accepted

Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: a multicenter prospective study
Sophie Servais, Frédéric Baron, Chantal Lechanteur, Laurence Seidel, Etienne Baudoux, Alexandra Briquet, Dominik Selleslag, Johan Maertens, Xavier Poire, Wilfried Schroyens, Carlos Graux, Ann De Becker, Pierre Zachee, Aurélie Ory, Julie Herman, Tessa Kerre and Yves Beguin

→ To be published in Frontiers Immunology 2023

What did we do in 2022?

Publications on clinical trials

Submitted

Feasibility of co-transplantation of umbilical cord blood and third-party mesenchymal stromal cells after (non)myeloablative conditioning in patients with haematological malignancies.
Ann De Becker, Tessa Kerre, Johan Maertens, Frédéric Baron, Carlos Graux, Ivan Van Riet, Chantal Lechanteur, Etienne Baudoux, Yves Beguin and Rik Schots, on behalf of the Transplant Committee of the Belgian Hematology Society.
Rejected by Cytotherapy
Will be resubmitted to another journal

What did we do in 2022?

Publications on guidelines

none

Regulatory affairs

New version of the SOP for the Belgian Transplant Registry in collaboration with the Belgian Cancer Registry (Y Beguin, Ulg)

Support letter for reimbursement of Prevemys post transplant

What are our future projects and ideas?

Publications

- MSC in double UCB SCT (A. De Becker, UZB): submitted
- In vitro and in vivo dose relevant AZA effect on Tregs subpopulations: applied to post-HSCT relapsing AML/MDS (C. Cassius, X Poiré, C. Graux, UCL): in preparation
- Busulfan dosage (T. Kerre, A. Delie, UZG): in preparation

Guidelines

Update Belgian vaccination guidelines post transplant / CAR-T: general guidelines for hematological patients in collaboration with the other committees? Or two separate publications?

Regulatory affairs

Reimbursement photophoresis (P Lewalle, Bordet, Y Beguin, Ulg)

Reimbursement vaccination after stem cell transplantation, Wallony (F Van Obbergh, UCL)

Reimbursement chimerism analysis (A Delie, UZG)

What are our future projects and ideas?

Clinical trials: new proposals for 2022-2023

- AZATARG trial for AML relapsed after SCT (X Poiré, UCL): pending budget – on hold
- Fludarabine dosing study for RIC SCT (A Delie, UZG): budget OK, EC pending)
- Fludarabine dosing study in LD chemotherapy before CAR-T infusion (A Delie, UZG): budget OK, EC pending)

What are our future projects and ideas?

Research project proposal

CRA support for the PI's of the currently recruiting trials: 1000 euro/included patient

- TJB0703 (MSC poor chimerism) (F. Baron, Ulg) → support needed: 2-3 patients expected to be enrolled in 2023
- TJT1203 (WIDEA) → support by STK, but not for CRA → 24 patients expected to be enrolled in 2023 → AL committee
- TJB1305 (Photopheresis) (P. Lewalle, Bordet) → no support needed
- TJB1703 (FM-PTCy vs FM-ATG) (F. Baron, Ulg) → support needed: 15-20 patients expected to be enrolled in 2023
- TRACE → no support needed (support by Horizon 2020)
- TOTAL # patients: 20 → 20.000 euro for 2023

What are our future projects and ideas?

Research project proposal

CRA support for new trials: 10.000 euro/trial

- Fludarabine dosis trial: no support needed at this moment

→ General question: do we have to wait for the BHS meeting to submit proposals, or can it be submitted at any tome or fixed times, eg every 3 months, as long as there's still budget available?

What are our future projects and ideas?

Committee on immune cell therapy?

Expand the SCT committee to BHS committee for stem cell transplantation and immmune cell therapy or

Create a new committe on cell therapy?

Thank you for you attention!